首页> 美国卫生研究院文献>BioMed Research International >Molecular Characterization of Heterologous HIV-1gp120 Gene Expression Disruption in Mycobacterium bovis BCG Host Strain: A Critical Issue for Engineering Mycobacterial Based-Vaccine Vectors
【2h】

Molecular Characterization of Heterologous HIV-1gp120 Gene Expression Disruption in Mycobacterium bovis BCG Host Strain: A Critical Issue for Engineering Mycobacterial Based-Vaccine Vectors

机译:牛分枝杆菌BCG宿主菌株中异源HIV-1gp120基因表达破坏的分子表征:工程基于分枝杆菌的疫苗载体的关键问题。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Mycobacterium bovis Bacillus Calmette-Guérin (BCG) as a live vector of recombinant bacterial vaccine is a promising system to be used. In this study, we evaluate the disrupted expression of heterologous HIV-1gp120 gene in BCG Pasteur host strain using replicative vectors pMV261 and pJH222. pJH222 carries a lysine complementing gene in BCG lysine auxotrophs. The HIV-1 gp120 gene expression was regulated by BCG hsp60 promoter (in plasmid pMV261) and Mycobacteria spp. α-antigen promoter (in plasmid pJH222). Among 14 rBCG:HIV-1gp120 (pMV261) colonies screened, 12 showed a partial deletion and two showed a complete deletion. However, deletion was not observed in all 10 rBCG:HIV-1gp120 (pJH222) colonies screened. In this study, we demonstrated that E. coli/Mycobacterial expression vectors bearing a weak promoter and lysine complementing gene in a recombinant lysine auxotroph of BCG could prevent genetic rearrangements and disruption of HIV 1gp120 gene expression, a key issue for engineering Mycobacterial based vaccine vectors.
机译:作为重组细菌疫苗的活载体的牛分枝杆菌卡介苗(BCG)是一种很有前途的系统。在这项研究中,我们使用复制载体pMV261和pJH222评估BCG Pasteur宿主菌株中异源HIV-1gp120基因的破坏表达。 pJH222在BCG赖氨酸营养缺陷型中带有赖氨酸互补基因。 HIV-1 gp120基因表达由BCG hsp60启动子(在质粒pMV261中)和分枝杆菌spp调控。 α抗原启动子(在质粒pJH222中)。在筛选的14个rBCG:HIV-1gp120(pMV261)菌落中,有12个显示部分缺失,两个显示完全缺失。但是,在所有10个rBCG:HIV-1gp120(pJH222)菌落中均未观察到缺失。在这项研究中,我们证明了在重组BCG赖氨酸营养缺陷型中,携带弱启动子和赖氨酸互补基因的大肠杆菌/分枝杆菌表达载体可以防止基因重排和HIV 1gp120基因表达的破坏,这是工程化基于分枝杆菌的疫苗载体的关键问题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号